Pulmatrix is a clinical-stage biotechnology company based in Lexington, Mass., developing a new class of inhaled therapies using its iCALM and iSPERSE platforms. Its lead candidate, PUR118 (an iCALM therapy), is being advanced toward Phase 2A efficacy studies in chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). The company is actively enrolling two Phase 1b studies of PUR118 in COPD patients and plans a clinical study of PUR118 in CF in the near future. Pulmatrix intends to use recent funding to accelerate these clinical programs and to expand its proprietary inhaled therapeutic platforms to build a broader product pipeline. The company has raised research funding totaling over $10 million, including grants from DARPA and NIAID. The announcement frames the funding as enabling completion of clinical studies to demonstrate safety and therapeutic benefit of its inhaled therapeutics. Pulmatrix is a Lexington, MA-based clinical-stage biotechnology company discovering and developing a new class of therapies to treat and prevent infectious and progressive respiratory diseases. Its approach focuses on host-targeted therapies that harness the airway and lungs' natural biophysical properties and host-defense mechanisms. The company's product pipeline includes PUR003 and next-generation formulations intended for respiratory indications. Pulmatrix plans multiple clinical trials in a number of respiratory diseases that the company said will initiate in 2010 and 2011. The company recently secured financing and grant support to accelerate R&D and clinical development. A $2.2M grant from NIAID will support preclinical studies to extend the spectrum and efficacy of PUR003 and advance formulations to IND-enabling toxicology studies.

Total raised

$46M

Funding rounds

3

Latest round

Series B

Latest activity

Aug 2011